TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06911112: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Sponsor: Neurocrine Biosciences · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$9,334,512

Rescue Site Savings

+$6,175,864

Unlock Full NCT06911112 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06911112 Rescue Dossier →